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INTRODUCTION 
 
 
 
 
 
 
             In health the volume and composition of body fluids vary within normal limits 
and the kidneys are largely responsible for maintaining this state. The kidneys also 
subserve a host of metabolic and endocrine functions. Chronic kidney disease is a 
pathophysiological process with multiple etiologies, resulting in inexorable 
attrition of nephron number and function leading to end stage renal disease. End 
stage renal disease is a clinical condition in which there has been an irreversible 
loss of endogenous renal function, of a degree sufficient to render the patient 
permanently dependent upon renal replacement therapy. 
            Cardiovascular disease is emerging as the most common cause of death in 
patients with end stage renal disease. The age adjusted cardiovascular 
complications and mortality is about 30 times higher in end stage renal disease 
than in general population1. Pre transplant cardiovascular disease is also a risk 
factor for post transplant cardiovascular disease. Besides the traditional risk 
factors like age, gender, etc there are many risk factors specific to chronic kidney 
disease like anemia, hyperparathyroidism, hyperhomocysteinemia, proteinuria, 
hypoalbuminemia, activated renin angiotensin system which contribute to 
cardiovascular disease. 
           Angina pectoris, myocardial infarction, dysrhythmia, cardiac failure, stroke 
and peripheral vascular disease are common in end stage renal disease2.  
Cardiomyopathy, whether clinically silent or not, is an independent predictor of 
cardiac morbidity and mortality3.  Natural history studies3-7 suggests that (1) 
cardiomyopathy predisposes to cardiac failure and death, and (2) ischemic heart 
disease results from and predisposes to cardiomyopathy, cardiac failure and death.  
            An understanding of the pathophysiology of cardiovascular diseases in 
chronic kidney disease enables prevention, early diagnosis and prompt 
interventions to control the complications. 
          This study done at Stanley Medical College, Chennai identifies the 
cardiovascular changes and complications found in patients with chronic kidney 
disease. 
 
 AIM OF THE STUDY 
 
1. To study the cardiac changes and complications in patients with chronic 
kidney disease. 
2. To study the incidence of left ventricular dysfunction, concentric left 
ventricular hypertrophy, pericardial effusion in chronic kidney disease 
patients using echocardiography. 
 
 REVIEW OF LITERATURE 
 
   Review of literature is discussed under the following headings: 
      1. Chronic kidney disease. 
 2. Stages of chronic kidney disease. 
 3. Pathophysiology of uremia.      
       4. Cardiovascular complications of chronic kidney disease. 
       5. Pathophysiology of cardiovascular diseases in chronic kidney disease. 
      6. Uremic cardiomyopathy. 
      7. Heart failure. 
      8. Ischemic heart disease. 
      9. Pericardial diseases. 
      10. Heart murmurs and valvular abnormalities. 
      11. Cardiac arrhythmias. 
      12. Echocardiography. 
 
 
 
 
 
 
  
CHRONIC KIDNEY DISEASE: 
 
            The kidney has such considerable functional reserves that in healthy men 
reduction of renal mass by half cause no disturbances of clinical importance. 
However when renal mass is reduced further, excretion of waste products of 
metabolism cannot be achieved without their levels rising in serum and when 
sufficient nephron loss occurs, control of many physiological processes become 
inadequate and symptoms and abnormal physical signs results. 
           Chronic kidney disease is a pathophysiological process with multiple 
etiologies, resulting in inexorable attrition of nephron number and function leading 
to end stage renal disease. End stage renal disease is a clinical condition in which 
there has been an irreversible loss of endogenous renal function, of a degree 
sufficient to render the patient permanently dependent upon renal replacement 
therapy (dialysis or transplantation) in order to avoid life threatening uremia. 
Uremia is the clinical and laboratory syndrome, reflecting dysfunction of all organ 
systems as a result of untreated or undertreated chronic renal failure. 
 
 
 
 
  STAGES OF CHRONIC KIDNEY DISEASE8. 
              A widely accepted international classification divides chronic kidney 
disease into a number of stages defined by clinical estimation of glomerular 
filtration rate. 
 
STAGES OF CHRONIC KIDNEY DISEASE 
 
Stage      Description  
 
GFR in ml/min per 1.73 cm2 
 
 At increased risk  90(with CKD risk factors) 
1         Kidney damage with normal 
or increased GFR 
90 
2 Kidney damage with mildly 
decreased GFR 
60-89 
3 Moderately decreased GFR 30-59 
4 Severely decreased GFR 15-29 
5 Renal failure <15 (or dialysis) 
 
 
  PATHOPHYSIOLOGY OF UREMIA: 
             The finding that sera from patients with uremia exert toxic effects in a 
variety of biologic test systems has motivated a diligent search to identify the 
responsible toxins. The most likely candidates as toxins in uremia are the by 
products of protein and amino acid metabolism. Unlike fats and carbohydrates, 
which are eventually metabolized to carbon dioxide and water, substances that are 
easily excreted even in uremic subjects in lungs  and skin, the products of protein 
and amino acid metabolism depend largely on the kidneys for excretion. Urea 
represents some 80 percent or more of the total nitrogenous end products of 
protein metabolism and others include substances such as guanidine, methyl and 
dimethyl guanidine, Creatinine and guanidino succinic acid. As with urea, 
guanidines are derived at least in part from urea cycle. 
              Uremic symptoms correlate only in a rough and inconsistent way with the 
concentration of urea in blood. Urea may account for some of the clinical 
abnormalities including anorexia, malaise, vomiting, and headache. On the other 
hand, elevated levels of plasma guanidino succinic acid acts by interfering with 
the activation of platelet factor III by adenosine diphosphate, and contributes to 
the impaired platelet function seen in chronic kidney disease. Creatinine may 
cause adverse effects following conversion to metabolites such as methyl 
guanidine. 
              Nitrogenous compounds of larger molecular weight are also retained in 
chronic kidney disease. A toxic role for these substances has been suggested 
because of the impression that patients treated with intermittent peritoneal dialysis 
are less troubled with neuropathy than patients maintained on chronic 
hemodialysis, despite higher levels of urea and Creatinine in blood in the former 
group. Since the clearance of small molecules depends mainly on blood and 
dialysate flow rates which are higher with hemodialysis, whereas clearance of 
larger molecules depend more on membrane surface area and time, which are 
greater with peritoneal dialysis this latter therapy may be more effective in 
removing substances of larger molecular weight. 
 
             The role of ‘middle molecules’ in the uremic syndrome remains 
speculative. Not all middle sized molecules accumulate in uremic plasma because 
of decreased renal excretion alone. The kidney normally catabolises a number of 
circulating plasma proteins and polypeptides, with reduced renal mass this 
capacity may be impaired greatly. Furthermore plasma levels of many polypeptide 
hormones (including parathyroid hormone, insulin, glucagon, growth hormone,  
leutinising hormone and prolactin) rise with chronic renal failure. Of these 
excessive parathyroid hormone may be important because of its adverse effects on 
several organ systems. 
 
             In chronic renal failure, compensatory and adaptive mechanisms remain 
within acceptable limits until the glomerular filtration rate is about 10-15 ml/min. 
The popular explanation for continuing function is the ‘intact nephron hypothesis’ 
which states that when most nephrons are non-functioning, the remaining few 
function normally and they produce an increased volume of filtrate and then 
tubules also respond by excreting fluid and solutes in amounts which maintain 
external balance. 
 CARDIOVASCULAR COMPLICATIONS OF END-STAGE RENAL DISEASE: 
             End-stage renal disease and cardiac disease seem to be inextricably linked. 
Approximately half of all deaths seen in end-stage renal disease patients are 
attributed to cardiovascular disease; this figure is remarkably similar throughout 
the world9-14. Cardiovascular disease is frequently present in patients starting end-
stage renal disease therapy and undoubtedly contributes to the excessive 
cardiovascular morbidity and mortality seen in patients on renal replacement 
therapy. Pre clinical cardiovascular abnormalities are even commoner. Non-
invasive studies, principally using echocardiography have consistently shown that 
upto 80 percent of patients starting on renal replacement therapy have structural or 
functional abnormalities of the left ventricle3,15-18. In the Canadian hemodialysis 
morbidity study, the annual incidence of myocardial infarction or angina requiring 
hospitalization was 10 percent per year19. A similar incidence was observed for 
pulmonary edema19. 
 
PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC                 
KIDNEY DISEASE: 
             In addition to traditional risk factors which are frequently present in 
patients with chronic kidney disease, there are few more risk factors specific to 
chronic kidney disease which contributes to the increased burden of cardiovascular 
diseases.  
        TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASES 
 
       Hypertension                                            Older age  
       Diabetes mellitus                                     Male gender  
       High LDL                                                Physical inactivity 
       Low HDL 
       Smoking 
       Left ventricular hypertrophy    
                                          
        CHRONIC KIDNEY DISEASE RELATED RISK FACTORS  
     SPECIFIC TO CKD    EMERGING RISK FACTORS 
 
  
Blood pressure 
Anemia                                            
Calcium phosphate 
Sodium retention 
Hypervolemia  
Hypoalbuminemia  
Angiotensin II 
Aldosterone 
Depression and sleep disorders 
 
    
 ↑ Homocysteine  
 ↑ Nitric oxide synthesis 
   
 ↑ Lipoprotein (a) 
 
 ↑ Insulin resistance 
  
              For every increase of systolic blood pressure by 5 mm of Hg and every 10 
year rise in age, there is an increase in the risk of left ventricular hypertrophy by 
11 and 25 percent respectively20. The male gender has an increased risk by 40 
percent20. 
ANALYSIS OF RISK FACTORS: 
1. HYPERTENSION: 
              Hypertension is a strong predictor for left ventricular hypertrophy, cardiac 
dilatation, cardiac failure, ischemic heart disease and worsening of atherosclerosis. 
Blood pressure is an important determinant of left ventricular mass more so in 
uremics. There is a blunting of nocturnal dip in blood pressure in uremics. 
Whether the non-dipping leads to left ventricular hypertrophy or left ventricular 
hypertrophy is the cause of the blunted nocturnal dip, this puts the patients at 
higher risk for vascular disease21. Aggressive control of blood pressure reduces the 
rate of nephron loss in progressive renal impairment in the pre dialysis phase. It is 
not just hypertension; even hypotension is associated with increased 
cardiovascular morbidity and mortality. Impairment of cardiac perfusion during 
diastole particularly in the presence of left ventricular hypertrophy or decreased 
aortic compliance leads to ischemic myocardial damage. Increase in age, 
hypertension, increase in vessel wall calcium leads to stiff arteries which in turn 
leads to high systolic and low diastolic pressures. While high systolic blood 
pressure leads to increased myocardial work, low diastolic blood pressure impairs 
the myocardial circulation in diastole. For any given systolic pressure a greater 
pulse pressure correlated with increased risk of death. A pulse pressure of greater 
than 50 mm of Hg carries a higher risk22.  
     2. ANEMIA: 
              The kidney being main source of erythropoietin, anemia is apparently 
an integral part of advancing renal failure. Anemia exerts an independent effect 
on the cardiovascular system. For every 1 g/dl drop in mean hemoglobin, the 
risk of cardiac failure increases by 25%, echocardiographically demonstrable 
left ventricular hypertrophy by 42%, and risk of death increases by 14%23. 
Even moderate degree of anemia developing early in chronic renal disease, are 
associated with progressive cardiac enlargement.     
 PATHOGENESIS OF CARDIOVASCULAR DISEASE IN ANEMIA 
                                                        ANEMIA 
                                                         
     
    ↓ RBC                                                                           ↓ Hemoglobin 
    ↓ Viscosity                                                                    ↓ O2 delivery 
    ↓ Peripheral resistance                                                  ↑ Sympathetic activity 
 
     ↑Venous return                                                    ↑ Heart rate & Venous tone 
 
                                                 ↑ Cardiac output 
 
 
                                                 ↑ Arterial volume  
 
     ↑ LV wall tension                                                            ↑ Arterial tension 
Adaptive & Maladaptive LVH                                                     Arteriosclerosis 
    
1. CALCIUM, PHOSPHORUS AND PARATHORMONE IN CKD: 
 
            Progressive nephron loss is associated with phosphate retention and 
hypocalcemia. This triggers increased parathormone activity. Secondary 
hyperparathyroidism results in impaired calcitriol synthesis, increased skeletal 
resistance to parathormone, increased parathyroid cell hyperplasia, decreased 
expression of calcium receptors. These culminate in decreased cardiac 
contraction. Increased calcium phosphate product promotes metastatic 
calcification. Coronary artery calcification precipitates conduction defects, 
arrhythmias and myocardial fibrosis. 
 
2. HYPOALBUMINEMIA – MALNUTRITION: 
            Hypoalbuminemia is emerging as a powerful risk factor for 
cardiovascular morbidity and mortality especially in hemodialysis patients. 
Malnutrition also can lead to low folate, B12 levels and low arginine intake 
leading further to hyperhomocysteinemia and impaired nitric oxide synthesis. 
Uremia is a state of chronic inflammation. Inflammation decreases albumin 
synthesis and increases albumin fractional catabolic rate. 
 
3. ANGIOTENSIN II: 
            The renin angiotensin system is activated in most of the renal diseases 
especially in diabetics. Angiotensin II is not only a vasoactive peptide but also 
a true cytokine that regulates cell growth, inflammation and fibrosis. 
Angiotensin II increases TNF-α production. It also upregulates other pro-
inflammatory mediators like IL-6, NF-kB, etc. The various metalloproteinases 
induced by Angiotensin II leads to proliferation, migration and hypertrophy of 
vascular smooth muscles and promotes matrix expansion and fibrosis24. 
 
6. HYPERHOMOCYSTEINEMIA: 
            Homocysteine is a strong predictor of cardiovascular disease. It 
enhances vascular smooth muscle proliferation, increases platelet aggregation 
and acts on the coagulation cascade and fibrinolytic pathway directly inducing 
a prothrombotic environment. The proposed mechanisms of homocysteine 
toxicity are oxidative stress through production of oxygen species, binding to 
nitric oxide and production of homocysteinylated or acylated proteins. 
 
7. LIPIDS:  
             Renal dyslipidemia is reflected in an abnormal apolipoprotein profile – 
reduced concentration of apo A containing lipoprotein in HDL and increased 
concentration of partially metabolized triglyceride rich apo B containing 
lipoprotein in VLDL, IDL and LDL. There is preferential rise in levels of IDL 
and small dense LDL. A significantly decreased apo A-II to apo C-II ratio is 
the hallmark of altered lipoprotein composition in renal disease. All of these 
factors promote accelerated atherosclerosis. 
   UREMIC CARDIOMYOPATHY:  
  ETIOLOGY: 
         Left ventricular hypertrophy can occur in response to both volume 
overload and pressure overload. Volume overload leads to proliferation of 
sarcomeres in series, with cardiac dilatation and augmented cardiac output, by 
the Frank-Starling mechanism25. In this situation to maintain wall tension Left 
ventricular hypertrophy occurs in accordance with Laplace’s law (Tension= 
pressure x radius/2 x wall thickness). In situation of pressure overload, 
sarcomeres proliferate in parallel with existing sarcomeres, leading to wall 
thickening and increased cavity pressure25. This increased cavity pressure 
allows cardiac output to be maintained, but the trade-off is increased wall 
stiffness. Subjects with end stage renal disease are exposed to many factors 
leading to volume overload, such as anemia, arteriovenous connection and 
fluid overload26. They are also frequently exposed to factors that lead to 
pressure overload particularly hypertension. 
        The continuation of long term pressure and volume overload, with 
concomitant cardiac hypertrophy, is accompanied by a progressive, eventually 
lethal, growth abnormality that can be called as cardiomyopathy of overload27. 
Thus the adaptive hypertrophic response to both volume and pressure overload 
becomes maladaptive, particularly if cell death or cardiac fibrosis occurs. 
 
        ETIOLOGIC MECHANISMS OF UREMIC CARDIOMYOPATHY 
          
         Hypertension                                                       Anemia 
         Older age                                                             Fistula  
         Diabetes                                                              Volume overload 
         Anemia                                                                Hypertension         
                      
            Concentric LV                                                       LV dilatation with 
              hypertrophy                                                             hypertrophy 
                                                                                                                            
                                                                                                                       
                                                                                                                                                              
 
 
  
           Diastolic dysfunction                                            LV dilatation 
                                                                                         Cell death and fibrosis 
 
 
                                UREMIC CARDIOMYOPATHY                    
 
 
 
 
                                                                                          Systolic dysfunction 
 
             In chronic uremia, not only is cardiac overload sustained, but other 
conditions that predispose to cell death occur. Hyperparathyroidism may cause left 
ventricular hypertrophy28, but in chronic uremia it may be responsible for 
inadequate hypertrophy29, cell death30 and myocardial fibrosis. In addition 
ischemia whether caused by large or small vessel disease also lead to cell death 
and fibrosis. 
DIAGNOSIS: 
           Echocardiography has been the most widely used non-invasive test in the 
general population because of accuracy, simplicity, lack of radiation and relatively 
low cost. Information on left ventricular mass, volume and contractility can be 
obtained, as well as assessment of regional wall abnormalities and valvular 
function. Aortic and mitral valve calcification has also been reported. Left 
ventricular mass measured by echocardiography is a strong predictor of 
cardiovascular morbidity. 
           In dialysis patients, M-mode echocardiography has been shown to have 
high reliability and validity31. Ventricular diameter, however increase with fluid 
reaccumulation following dialysis. This influences the LV mass index so that a 
high mass is calculated32. In practical terms, the impact of hypervolemia on the 
calculation of LV mass is small of the order of 9 g/m2 for each litre of fluid 
accumulated. 
 
  HEART FAILURE IN CHRONIC KIDNEY DISEASE: 
           Heart failure may result from systolic or diastolic dysfunction, the latter 
occurring as a result of concentric or eccentric hypertrophy. Ischemic heart disease 
is an additional independent risk factor. 
 
CARDIAC DISEASE PREDISPOSING TO HEART FAILURE IN 
CHRONIC UREMIA 
             Concentric LV hypertrophy                              Coronary artery disease 
             LV dilation ± LV hypertrophy                          Non-atherosclerotic disease  
            
            Cardiomyopathy                                                 Ischemic heart disease  
 
           Systolic dysfunction        Diastolic dysfunction                                                      
 
 
                                                                  HEART FAILURE                  
 
          Among patients with diastolic dysfunction, congestive heart failure results 
from impaired ventricular relaxation which leads to an exaggerated increase in LV 
end diastolic pressure for a given increase in LV end diastolic volume. As 
ventricular volume increases, failure to have adequate hypertrophy leads to an 
increase in wall stress and increase in LV end diastolic pressure. This increase in 
LV end diastolic pressure leads to increased pulmonary capillary pressure and 
dyspnoea. 
 
 
 
   ISCHEMIC HEART DISEASE IN CKD: 
           ETIOLOGY 
           Symptomatic myocardial ischemia usually results from coronary artery 
disease, but it is nonatherosclerotic in origin in about a quarter of patients33,34. 
Disorders at several levels may contribute: large and medium size arterial disease , 
with luminal narrowing and inability to dilate when required; small vessel 
disease35,36 and an inappropriately small density of capillaries relative to 
myocardial mass37,38. 
 
ETIOLOGIC MECHANISMS OF ISCHEMIC HEART DISEASE IN 
CHRONIC UREMIA   
                Hypertension                                     High cholesterol/HDL 
                Diabetes                                             Oxidized LDL                         
                Dyslipidemia                                      Lipoprotein remnants 
                Smoking                                             Lipoprotein (a)        
              
              Atherosclerotic disease  
                                                                                   ISCHEMIC HEART 
                                                                                         DISEASE 
              Nonatherosclerotic disease  
 
             
                LV hypertrophy                                               Diabetes 
                                                                                              
               Small vessel damage                                         Hypertension                                
                                                                              
                Anemia                                                            Calcification 
              In the absence of critical coronary artery disease, ischemic symptoms may 
result from a reduction in coronary vasodilator reserve and altered myocardial 
oxygen delivery and use. The presence of left ventricular hypertrophy and anemia 
may predispose to nonatherosclerotic ischemia. As the demand for oxygen 
increases, the coronary vasculature dilates above basal, and a further increase in 
myocardial oxygen requirement may not be met with adequate increases in 
coronary flow, especially if there are pathologic changes in the large or small 
coronary vessels. In coronary artery stenosis, during hyperemia the relative flow 
progressively decreases when the degree of stenosis is above 40% and does not 
differ significantly from basal flow when the stenosis is 80% or greater. 
             Small vessel disease can occur in LV hypertrophy, diabetes and uremia. In 
LV hypertrophy, small vessel smooth muscle hypertrophy and endothelial 
abnormalities can diminish the coronary reserve. Diabetics may have 
abnormalities of small coronary arteries with endothelial proliferation, 
subendothelial fibrosis, exudative deposits of hyaline in the intima, and 
atheromatous thickening with cholesterol clefts. 
             A decrease in coronary reserve may result from small vessel calcification, 
the calcium x phosphorus product has been reported to be significantly elevated in 
symptomatic end stage renal disease without significant coronary artery disease, 
when compared to those with significant lesions.  
 
 The length density and surface density of capillaries in the heart of uremic rats 
were significantly more reduced than in rats with Goldblatt hypertension matched 
for LV weight and for blood pressure level37. Hyperparathyroidism plays a critical 
role in the genesis of impaired energy production, transfer and utilization by the 
myocardium39.  
 
DIAGNOSIS: 
             Ischemic heart disease is not a homogenous entity, especially in end stage 
renal failure patients. The following factors make the diagnosis of ischemic heart 
disease difficult.  
 
1. Many patients have nonatherosclerotic ischemic heart disease, with 
typical symptoms of angina but patent coronary arteries. 
2. It is also known that many end stage renal failure patients with advanced 
anatomic coronary artery disease are asymptomatic, without typical 
electrocardiographic changes. 
3. The noninvasive tests used to diagnose cardiac diseases in the general 
population are problematic in dialysis patients. 
4. Creatine phosphokinase, including its MB fraction, and lactate 
dehydrogenase levels are elevated in renal failure patients, which makes 
the diagnosis of acute myocardial infarction more difficult40,41. 
 PERICARDIAL DISEASES: 
          Pericarditis is the consequence of an inflammation of the pericardium, 
the serous membrane enclosing the heart and the root of the great vessels. In 
azotemic patients pericarditis can be due to a number of causes including 
bacterial, viral or tubercular infections, diseases involving serous 
membranes such as systemic lupus erythematosus or some condition of 
azotemia itself. Pericarditis occurs in patients with both acute and chronic 
renal failure, with greater frequency in the latter. With the advent of dialysis 
therapy for the treatment of acute and chronic renal failure, the occurrence of 
chronic pericarditis has decreased. 
         In the azotemic patient, the pericarditis usually appears late in the 
uremic stage. It clears quickly when dialysis is started. 
 
PATHOLOGY AND PATHOGENESIS: 
         Fibrinous aseptic inflammation is the hallmark of uremic pericarditis. 
Distribution of the inflammation can be diffuse or localized with areas of 
adhesion between the parietal and visceral layers of pericardium. An 
increase in vascularity occurs as the pericardial membranes thicken with 
movement between the layers, blood vessels are broken and causing 
formation of a serosanguinous effusion loculated between adherent fibrous 
bands. The volume of effusion may grow if the time of inflammation is 
prolonged, the patient becomes edematous with intravascular movement of 
fluid into pleural, peritoneal and pericardial spaces or heparin is given for 
dialysis. Serious life threatening complications result from acute or chronic 
compression of heart, which causes a decrease in cardiac output. This can 
happen rapidly as a result of accumulation of fluid in a limited space 
(tamponade) or slowly from chronic thickening and scarring of the 
membrane (constriction). 
        Since pericarditis appears late in the course of renal failure and is 
reversed by dialysis, it can be assured that both the presence of dialyzate 
toxins and time of exposure have etiological roles. As with other signs or 
symptoms of uremia no single toxin has been implicated. Small molecules 
that clear rapidly with conventional dialysis may play a role, but larger 
molecules might also be involved. 
 
SYMPTOMS AND SIGNS: 
      The first manifestation of pericarditis is usually chest pain. The patient 
will report substernal discomfort which is typically worse when lying 
down, alleviated when sitting up and leaning forward. This may be due to 
the frequent posterior location of the pathological changes. On 
examination, a pericardial friction rub is usually noted. The rub is of two 
or three components timed with the heart cycle. The sound is scratchy or 
grating like rubbing two pieces of sand paper together. Low grade fever 
and leukocytosis may also be noted.      
 
 
                  CLINICAL FEATURES OF UREMIC PERICARDITIS 
 
     SYMPTOMS: 
            Chest pain 
            Dyspnoea 
            Orthostatic dizziness 
            Decrease in urine output 
            Rapid weight gain 
 
     SIGNS: 
           Pericardial friction rub 
           Fever  
           Mental confusion 
           Edema, ascites, anasarca 
           Hypotension 
           Pulses paradoxus (tamponade) 
 
     LAB RESULTS: 
           Cardiomegaly on X-ray 
            Leukocytosis 
           Atrial arrhythmias 
 
COMPLICATIONS: 
          Cardiac tamponade is the most serious, life threatening acute 
complication. Fluid accumulating in a poorly compliant compartment with 
thickened membranes leads to a decrease in cardiac output and hypotension. 
The neck veins are engorged. The heart is enlarged on percussion, cardiac 
sounds are muffled. A paradoxical pulse is often present. 
          Long standing asymptomatic, subclinical pericarditis can lead to 
constriction of the heart as the pericardial membrane tightens. Uremia can 
re-activate tuberculosis, which can cause an indolent pericarditis, later 
manifesting with signs and symptoms of constriction. 
 
 DIAGNOSIS: 
         A triangular shaped, “water bottle”, heart may be noted by chest X-ray 
examination. Low voltage complexes in electrocardiograms are also typical 
of effusion. Echocardiography is the definitive diagnostic procedure for 
detecting fluid in pericardial space. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        PARASTERNAL LONG-AXIS ECHOCARDIOGRAM SHOWING 
               MINIMAL PERICARDIAL EFFUSION 
                             
 
 
                                     RECORDED AT END-DIASTOLE 
 
                                     
                                     
          
 
                                     RECORDED AT END-SYSTOLE: 
 
 
                                     
 
 
 
At end-systole, a mild pericardial effusion (arrows) is seen.  
Ao-aorta; Dao-descending aorta; LA-left atrium; LV-left ventricle.  
 
 
 
PARASTERNAL LONG-AXIS ECHOCARDIOGRAM                
SHOWING MILD PERICARDIAL EFFUSION. 
 
 
 
 
                                      
 
 
             Echo-free space in the posterior interventricular groove (arrow). 
  
             A smaller anterior echo-free space (downward-pointing arrow).  
  
 LA-left atrium; LV-left ventricle; RVOT-right ventricular outflow     
tract. 
 
 
  
 
 
 
 
 
 
 
 
PARASTERNAL LONG-AXIS ECHOCARDIOGRAMS SHOWING MILD (A) 
AND MODERATE TO LARGE (B) PERICARDIAL EFFUSION 
 
                    
                 
                       
                                            
                                     
A: Mild pericardial effusion.There is an approximately 1-cm space 
between the epicardium and pericardium (arrow).  
                   
B: A larger pericardial effusion is present both anteriorly and 
posteriorly (arrows). 
Ao-aorta; LA-left atrium; LV-left ventricle; RVOT-right ventricular 
outflow tract.  
B 
  HEART MURMURS AND VALVULAR ABNORMALITIES: 
         Heart murmurs and valvular abnormalities are common in chronic 
renal failure patients. Calcification of valves, infectious and non- infectious 
endocarditis can occur in patients with chronic renal failure. Heart murmurs 
may be present without obvious underlying valvular abnormalities and are 
probably evoked by anemia, hyper adrenergic tone and volume and pressure 
overload. Early diastolic murmurs of aortic or pulmonary regurgitation, 
generally related to pressure and volume overload, can appear during 
advanced stages of renal failure and often disappear following hemodialysis. 
Cervical venous hum can also occur in these patients. 
 
CARDIAC ARRHYTHMIAS: 
         Cardiac arrhythmias because of their episodic nature makes 
identification and characterization difficult. Ventricular ectopic beats 
(couplets, non-sustained ventricular tachycardias) can occur. The frequency 
of ventricular ectopic beats appeared to vary directly with resting heart rate. 
The independent risk factors for the presence of Ventricular arrhythmias 
were, age over 55 years and left Ventricular dysfunction. 
         
 
Factors contributing to the development of cardiac arrhythmias in patients 
with chronic renal failure include: 
i) Underlying cardiac disease 
ii) Left ventricular hypertrophy, left ventricular dysfunction. 
iii) Coronary artery disease. 
iv) Pericardial disease. 
v) Cardiac calcification. 
vi) Hemodialysis (rapid changes in serum electrolytes). 
vii) Hyperadrenergic state. 
viii) High calcium phosphorous product. 
 
CARDIAC CHANGES AFTER RENAL TRANSPLANTATION: 
            Left ventricular systolic, diastolic volumes and ventricular 
mass decreases, ejection fraction increases after renal transplantation. 
There have been a number of reports documenting dramatic 
improvements in cardiac function in patients with severe dilated 
cardiomyopathy42,43. 
 
                            
            
                                  ECHOCARDIOGRAPHY 
 
           Echocardiography is one of the frequently used techniques for 
diagnosing cardiovascular diseases. It is so versatile, with clinical 
application in the entire spectrum of cardiovascular diseases. 
Echocardiography uses high frequency ultrasound to evaluate the 
structural, functional and hemodynamic states of cardiovascular 
diseases. 
           An echocardiographic examination begins with trans thoracic 
two dimensional (2D) scanning from four standard transducer 
positions: the parasternal, apical, subxiphoid and suprasternal 
windows. Quantitative measurements of cardiac dimensions, area and 
volume are derived from 2D images or 2D derived M-mode. In 
addition, 2D Echocardiography provides the framework for Doppler 
and color-flow imaging. 
         Doppler Echocardiography measures blood-flow velocities in the 
heart and great vessels and is based on the Doppler effect. The most 
common uses of Doppler Echocardiography are pulsed and continuous 
waveforms. Pulsed wave Doppler is used in determining peak-flow 
velocity, valvular pressure gradient, pressure half-time, dynamic left 
ventricular outflow tract gradient, etc. Colour flow imaging based on 
Pulsed  wave  Doppler principles,  displays  intracavity  blood  flow  in  
three colors (red, blue, green) or their combinations, depending on the 
velocity, direction and extent of turbulence. Tissue Doppler provides 
means for measuring and displaying cardiac wall motion velocities. 
Tissue Doppler is used to evaluate regional and global diastolic 
function and it has been noted that mitral annulus velocity measured 
by Tissue Doppler is an indicator of myocardial relaxation, relatively 
unaffected by preload or afterload. 
           
                                         
                                        
                                   
 
 
 
 
 
 
 
 
 
 
                                      MATERIALS AND METHODS 
 
               The study was conducted in patients with chronic kidney disease 
admitted in Stanley Medical College Hospital during the period August 2005 
to September 2006. 
 
INCLUSION CRITERIA: 
     The following criteria were used in selection of cases: 
1) Patients who were known chronic kidney disease patients.  
2) Patients who were symptomatic for 3 months or more. 
3) Patients with serum creatinine more than 3 mg% and creatinine 
clearance <30 ml/min. 
4) Patients with bilateral contracted kidneys on abdominal ultra 
sonogram with poor corticomedullary differentiation and type 2 or 
type 3 parenchymal changes. Patients with Autosomal Dominant 
Polycystic Kidney Disease and Obstructive Nephropathy were also 
included in the study though they did not have contracted kidney due 
to the underlying disorder. 
 
 
 EXCLUSION CRITERIA: 
1) Patients who were known valvular heart disease, coronary heart                     
disease, diabetes mellitus,etc.. 
2) Patients who were known hypertensive for years before the onset  
of chronic kidney disease. 
3) Patients who underwent dialysis after admission. 
4) Patients above 50 years of age. 
5) Patients who were alcoholics. 
 
               In all patients, a detailed history was taken, with special interest to 
the duration of symptoms was noted. Cardiovascular symptoms, like 
dyspnoea, chest pain, pedal edema, pallor were noted. Blood pressure was 
measured thrice and the average was taken. Cardiovascular examination was 
done. Complete hemogram, blood urea, serum creatinine, serum electrolytes, 
serum calcium, phosphorus and uric acid, serum lipid profile were measured. 
Patients were also subjected to abdominal ultra sonogram and chest X-ray.  
               Creatinine clearance had been calculated in all patients using the 
CockCroft-Gault equation: 
 
      Estimated Creatinine       =    ( 140 –  age )  x  body weight (kg ) 
       clearance(ml/min)                  72  x  serum creatinine (mg / dl) 
 
             This equation is for men. It is multiplied by 0.85 for women.  
 
Presence of cardiomegaly, pulmonary interstitial edema, pleural effusion 
were looked for in chest X-ray posteroanterior view. Evidence of left 
ventricular hypertrophy, low voltage complexes, ischemic changes were 
looked for in electrocardiogram. 
              Finally Echocardiography was done. The following parameters 
were looked for: 
1) Chamber size: 
        In the 2D and M-mode echocardiography the measurements of 
the interventricular septum, left ventricular posterior wall thickness, 
left ventricular internal diameter was made in both systole and 
diastole. Patients with interventricular septal thickness and left 
ventricular posterior wall thickness in diastole more than 1.1 cm 
represents concentric left ventricular hypertrophy. It is difficult to 
differentiate physiologic hypertrophy and pathologic hypertrophy. 
To avoid this, Relative wall thickness was calculated in all patients 
using the following equation: 
 
Relative wall thickness  =   IVS(D) X LVPW(D) 
                                                                LVID(D) 
  
             Relative wall thickness > 0.45 cannot occur in physiologic 
hypertrophy  and it signifies pathologic hypertrophy44. 
              In the parasternal long axis view, left ventricular internal diameter 
         in diastole more than 5.6 cm represents dilated left ventricle. Left atrial 
          antero posterior diameter more than 3.8 cm represents dilated left   
          atrium. 
 
2) Systolic function: 
         The systolic function is assessed mainly by M-mode 
measurements. Ejection fraction and fractional shortening are the 
two parameters used. The Ejection fraction is defined as the ratio of 
stroke volume to end-diastolic volume. 
             Ejection fraction = Enddiastolic volume - Endsystolic volume  x 100 
                                                         End diastolic volume 
 
             Normal values of Ejection fraction are 55 to 75 45. 
 
 
              
Grading of systolic dysfunction: 
i) Mild          45  to 55 %. 
ii) Moderate   35  to 45 %. 
iii) Severe       less than 35%. 
 
            Fractional shortening is calculated by the following equation: 
   Fractional shortening  =   LVID(D)  -  LVID(S)      X 100 
                                                LVID(D) 
 
3) Diastolic function: 
            Diastolic function is assessed by Pulsed wave Doppler using 
the E/A measurements. E (m/s) indicate mitral flow which causes 
ventricular filling following opening of the mitral valve. A (m/s) 
indicates ventricular filling due to atrial systole. E/A is normally 
more than 1. Less than 1 indicates diastolic dysfunction. 
 
Diastolic dysfunction can be graded as follows: 
  Grade 1 = impaired relaxation 
  Grade 2 = pseudonormalised pattern 
  Grade 3 = reversible restrictive pattern 
  Grade 4 = irreversible restrictive pattern 
 4) Left ventricular wall motion abnormalities: 
          Left ventricular performance is assessed by many ways. Left 
ventricular wall is divided into a number of segments. Determining 
the motion of each segment provides the wall motion score. 
 
5) Pericardial effusion: 
The Pericardial effusion is quantified by the amount of echo-free 
space surrounding the heart. The Pericardial effusion can be 
graded as 
 Minimal pericardial effusion: Posterior atrioventricular groove      
shows echo free space, this is seen in systolic phase only. It   
represents normal pericardial fluid. 
                     Mild pericardial effusion: Echo free space < 1 cm. 
                     Moderate pericardial effusion: Echo free space 1 – 2 cm. 
                      Large Pericardial effusion: Echo free space > 2 cm. 
 
 
 
 
6) Valvular abnormalities : 
          The valves were looked for stenotic lesions, regurgitant 
lesions, calcifications or vegetations. 
 
    
 
 
 

                                  OBSERVATION AND RESULTS 
 
             The study included a total of 54 patients which included 40(74%) males 
and 14(26%) females. 
                      
  MALE 
 
   FEMALE 
 
   TOTAL 
 
 
  40(74%) 
 
     14(26%) 
 
 
       54 
 
  
   AGE DISTRIBUTION: 
            The age of the patients included in the study varied from 13 to 48 years. 
                              
 
                              
 
 
 
  
 
 
                Mean age(males) – 31 years             Mean age(females) – 26 years  
 
                Mean age(Total) – 30 years              
               
 
 
 
 
  Age  Male  Female  Total 
10 to 20    4     7      11 
21 to 30    15     1     16 
31 to 40    16     6       22 
41 to 50    5     0     5 
    40     14     54 
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  DURATION OF SYMPTOMS: 
          Duration of symptoms varied from 3 months to 3 years. 
 
          Duration  
 
      No. of patients 
 
   Less than 6 months           13(24.1%) 
   6 months to 1 year           22(40.7%) 
   More than 1 year           19(35.2%) 
               
 
  SYMPTOMS: 
             Easy fatiguability was present in all patients. Pedal edema and dyspnoea      
were the other common symptoms present. 
 
            Symptoms 
 
                No. of patients 
         Pedal edema                    50(92.6%) 
         Dyspnoea                     38(70.4%) 
         Chest pain                    10(18.5%) 
         Palpitation                     7(13%) 
         Vomiting                      7(13%) 
   
 
     PALLOR: 
        Pallor was present in 52(96.3%) cases. It was absent in 2(3.7%) cases. 
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                                        PE - Pedal edema                      V -  Vomiting      
                                        D  - Dyspnea                              P -  Palpitation 
                                        CP - Chest pain   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JUGULAR VENOUS PULSE: 
        Jugular venous pulse was normal in  35(64.8%) cases.  
        It was elevated in 19(35.2%) cases. 
  BLOOD PRESSURE: 
       Almost all patients had high blood pressure. The systolic BP varied from 130 
to 190 mm of Hg and the diastolic BP from 80 to 116 mm of Hg. The mean 
systolic BP in both males and females was 152 mm of Hg. The mean diastolic BP 
was 94 mm of Hg in males and 93 mm of Hg in females. 
 
  Systolic BP   No. of patients 
    < 140      20(37%) 
 140 – 160     21(38.9%) 
    >160     13(24.1%) 
 
    CARDIOVASCULAR SYSTEM: 
1. Apical impulse shifted down and out -  2 cases. 
2. Pansystolic murmur in mitral area -  2 cases. 
3. Ejection systolic murmur in the aortic area -  5 cases 
4.  Muffled heart sounds -  2 cases 
5. Only 1 patient had pericardial rub. 
    
  Diastolic BP   No. of patients 
    < 90      32(59.2%)  
  90 - 110      21(38.9%) 
     >110     1(1.9%) 
 HEMOGLOBIN: 
           Hemoglobin levels varied from 5 to 11 gm/dl, with the mean being 7.3 g/dl.  
 
    Hemoglobin(g/dl)      No. of patients 
   Less than 7 22(40.7%) 
   7 to 10 30(55.6%) 
   More than 10 2(3.7%) 
                 
     CREATININE: 
            The range of Creatinine 3.5 to 16.5 mg/dl and the mean was 9.4 mg/dl. 
    
   Creatinine(mg/dl)     No. of patients 
   Less than 5         3(5.5%) 
   5 to 10         31(57.4%) 
   More than 10         20(37.1%) 
 
  CREATININE CLEARANCE: 
            Creatinine clearance varied from 7 to 27 ml/min, amd the mean value was 
13 ml/min. 
 
 
 
                       
   
     CAUSES: 
        The most common cause of chronic kidney disease in the study was chronic 
glomerulonephritis. 
  
 
 
 
 
 
 
 
 
 
 
 
    
    CHEST X-RAY: 
 
 
               
 
 
 
 
 
 
 
 
 
Creatinine clearance  No. of patients 
Less than 15     37(68.5%) 
 15 to 30     17(31.5%) 
More than 30     Nil  
        Causes         No. of cases  
  CGN        48(88.9%)   
 IGA NEPHROPATHY         3(5.5%) 
OBSTRUCTIVE                     
NEPHROPATHY   
        2(3.7%) 
ADPKD         1(1.9%) 
  Normal         39(72.3%) 
 Cardiomegaly        12(22.2%) 
 Cardiomegaly with pulmonary 
interstitial edema 
      3(5.5%)  
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  ELECTROCARDIOGRAPHY: 
 
  
            1. LVH with pressure overload pattern – 10(18.5%) cases. 
 
            2. Low voltage QRS complexes – 2(3.7%) cases. 
 
 
 
   ECHOCARDIOGRAPHIC ABNORMALITIES:  
 
 
            Pericardial effusion and concentric left ventricular hypertrophy were the 
most common abnormalities detected in echocardiography. 
 
                     
    Pericardial effusion      25(46.3%)  
   Concentric LVH                 24(44.4%)  
    Dilated LV      14(25.9%)  
    Dilated LA      4(7.4%)  
   Systolic dysfunction      11(20.4%)  
   Diastolic  dysfunction      15(27.8%)  
   Normal       8(14.8%)     
              
          
 
 
 
  
           Systolic dysfunction -  11(20.4%)  
 
                            Mild         -   5 
 
                            Moderate -    3  
 
                            Severe      -   3 
               
          Diastolic  dysfunction  -  15(27.8%)  
 
                            Grade I       -   11 
                                  
                            Grade II      -    4 
 
          Other   abnormalities: 
 
                            Aortic valvular calcification  -  4 
                  
                            Moderate MR                         -  1 
 
                            Mild MR                                -   7   
 
                            MVPS(Incidental)                 -   1      
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DISCUSSION 
 
 
           The study included a total of 54 patients. Of these 54 patients, 40(74%) 
were males and 14 (26%) were females. The age of the patients varied from 13 to 
48 years, with majority of patients falling within 31 to 40 years group. The mean 
age was 30 years, with mean age in males being 31years and in females being 26 
years. 
          The duration of symptoms varied from 3 months to 3 years. 13(24.1%) 
patients had duration less than 6 months. 22(40.7%) patients had duration from 6 
months to 1 year. Rest of the patients had duration more than 1 year. 
         Easy fatiguability was the most common symptom which was present in all 
the patients. The next common symptom was pedal edema. It was present in 50 
patients. Dyspnoea on exertion was present in 38 patients. Dyspnoea may be due 
to anemia, volume overload or pulmonary congestion due to failing left ventricle. 
Chest pain was found in 10 patients. Of these 10 patients 7 were found to have 
concentric hypertrophy and rest 3 had dilated left ventricle. The cause of chest 
pain in concentric LVH group could be due to increased demand by the 
hypertrophied muscle mass or constriction of the smaller coronary vessels by the 
muscular contraction during systole. Chest pain can also be due to pericarditis, in 
which the pain is more on lying down posture and alleviated by sitting up and 
leaning forward. History of palpitation was obtained from 7 patients.   
 
CLINICAL FINDINGS: 
             Bilateral pedal edema was present in 52 patients. The remaining 2 patients 
who did not have pedal edema presented with vomiting, dyspnoea, easy 
fatiguability to the general medical out patient department, and on investigations 
they were found to have elevated renal parameters and subsequent work up 
confirmed the presence of Chronic Kidney Disease. Pallor was present in 52 
patients. JVP was normal in 35 patients and elevated in 19 patients. The patients 
with elevated JVP showed other features of volume overload like facial puffiness, 
ascites etc. 
             Almost all patients had high blood pressure. The mean systolic BP was 
152 mm of Hg and the mean diastolic BP was around 94 mm of Hg. About 39% of 
patients had moderate hypertension. One patient had severe hypertension. All the 
patients were receiving antihypertensives after admission during the study. 
            Examination of Cardiovascular System revealed the following findings.2 
patients had apical impulse shifted down and out. 2 patients had pansystolic  
murmur in mitral area. 5 patients had ejection systolic murmur in the aortic area. 
Only 1 patient had pericardial rub. 2 patients had muffled heart sounds. Rest of the 
patients had normal cardiovascular findings on clinical examination.    
           The patients with shifted apical impulse had dilated left ventricle on 
Echocardiography. The patients with pansystolic murmur had moderate mitral 
regurgitation. The patients with ejection systolic murmur, was anemic and did not 
have any organic lesion in Echocardiography. The possible cause for this murmur 
could be due to hyperdynamic circulation. 2 patients with muffled heart sounds 
had moderate pericardial effusion. 16 patients had bilateral fine crepitations in the 
base of lung fields. The remaining 38 patients had normal respiratory findings. 
 
          Almost all patients in the study had Hemoglobin less than 12 g/dl. The 
lowest value was 5 g/dl and the highest was 11g/dl. 22(40.7%) patients had severe 
anemia defined by Hemoglobin less than 7 g/dl. 30(55.6%) patients had 
Hemoglobin between 7 to 10 g/dl. Anemia is an independent risk factor for cardiac 
abnormalities. For every 1 g/dl drop in mean hemoglobin, risk of cardiac failure 
increases by 25%, Echocardiographically demonstrable left ventricular 
hypertrophy in 42% and the risk of death increases by 14%23.  
           Urea and creatinine were elevated in all patients. Lowest creatinine was 3.5 
mg/dl and highest was 16.5mg/dl. About 31(57.4%) patients had creatinine values 
ranging from 5 to 9 mg/dl and 20(37.1%) patients had creatinine value greater than 
10 mg/dl. Creatinine clearance evaluated by Cockcroft Gault formula, varied from 
7 to 27 ml/min. 37(68.5%) patients had Creatinine clearance less than 15 ml/min. 
          Analysis of the underlying primary diseases as the probable cause for 
chronic kidney disease revealed that chronic glomerulonephritis is the most 
common cause which was found in 48(88.9%) patients. 3 patients had biopsy 
proved IgA Nephropathy. 2 patients gave history suggestive of obstructive 
symptoms and found to have landed up in chronic kidney disease during follow 
up. One of the patients had bilateral abdominal masses, and ultrasound proved to 
have Autosomal Dominant Polycystic Kidney Disease. Patients with diabetes and 
long standing hypertension were excluded from the study, which explains the high 
incidence of chronic glomerulonephritis as the cause in this study. 
         Chest X-Ray was normal in 39(72.3%) patients. Cardiomegaly was seen in 
12(22.2%) patients. Cardiomegaly with pulmonary interstitial edema is seen in 
3(5.5%) patients. 
         ECG showed evidence of Left ventricular hypertrophy with pressure 
overload pattern in 10 patients. The diagnosis of left ventricular hypertrophy in 
ECG was made by using Sokolow-Lyon criteria. Many patients had non-specific 
ST-T changes. 2 patients had low voltage complexes. 
 
                           ECHOCARDIOGRAPHIC PROFILE 
 
1. PERICARDIAL EFFUSION: 
          Pericardial effusion was found in 25(46.3%) cases. It is the most common 
abnormality in the study. Frommer JP et al has reported an incidence of 
pericardial effusion in 18 out of 50(36%) patients46. Gupta et al reported an 
incidence of 8.8% in patients on maintenance hemodialysis47. Mild pericardial 
effusion defined as echo free space less than 1 cm was found in 23 cases and 
moderate effusion defined as echo free space between 1 and 2 cm was found in 2 
cases. Minimal pericardial effusion is normal and is defined when there is fluid in 
the posterior atrioventricular groove and echo free space is seen only in systole48. 
2 patients with moderate effusion had low voltage QRS complexes in ECG and 
cardiomegaly in chest X-Ray. About 5 patients in the study had no cardiac 
symptoms but proved to have pericardial effusion. Patients with mild effusion had 
only non-specific ST-T changes in the ECG. This shows that echocardiography is 
sensitive in diagnosing mild pericardial effusion. 
 
 2. CONCENTRIC LVH: 
           Concentric left ventricular hypertrophy is the second common abnormality 
detected next to pericardial effusion. It was found in 24(44.4%) patients. Patients 
with interventricular septal thickness more than 1.1 cm and the Relative wall 
thickness [RWT = PWD + IVSD / LVIDD], greater than 0.45 was taken as the 
criteria to diagnose concentric left ventricular hypertrophy. In a study done by 
Parfrey PS et al5 in Division of Nephrology, Salvation Army Grace General 
Hospital, Canada, 41% of patients had concentric left ventricular hypertrophy. 
Dai Y et al has reported an incidence of LVH in 52% of patients49. Gruppen MP 
et al has reported LVH in 47% of male patients and 39% of female patients50. The 
study by Gruppen et al was a Dutch cohort study done in young adult patients 
with end-stage renal disease since childhood. Echocardiographically proved left 
ventricular hypertrophy is an independent risk factor for cardiovascular morbidity 
and mortality51.  Lowering of cardiac size and increase in fractional shortening 
were both associated with reduced subsequent likelihood of cardiac failure51.  
These  associations were independent of baseline age, diabetes mellitus, ischemic 
heart disease, baseline echocardiographic parameters. 
The mean duration of illness in patients with concentric hypertrophy was 11 
months. The mean age of patients with concentric hypertrophy was 29.6 years. 
The mean BP in patients who had concentric hypertrophy was 152mm of Hg 
(systolic) and 94 mm of Hg(diastolic). ECG showed concentric left ventricular 
hypertrophy with pressure overload type in 10(18.5%) patients. Echocardiography 
showed concentric left ventricular hypertrophy in 24(44.4%) patients. 3 of the 24 
patients who had concentric left ventricular hypertrophy did not have cardiac 
symptoms. About 14 patients had normal ECG but proved to have left ventricular 
hypertrophy by Echocardiography. This signifies the role of Echocardiography in 
diagnosing left ventricular hypertrophy.  
          Increasing age, hypertension, anemia were the causes of concentric left 
ventricular hypertrophy in uremia5. Hyperparathyroidism can also cause left 
ventricular hypertrophy28. 
3. DILATED LEFT VENTRICLE: 
          Dilated left ventricle is defined as the left ventricular internal diameter in 
diastole more than 5.6cm. About 14(25.9%) patients in the study had dilated left 
ventricle. This was similar to the study done by Parfrey PS et al., which had  
dilated left ventricle in 28%5. Of the 14 patients with dilated left ventricle, 10 had  
 cardiomegaly and 2 patients had cardiomegaly and pulmonary interstitial edema 
on chest X-Ray. 4 out of 14 patients with dilated left ventricle had systolic 
dysfunction. The risk factors for dilated left ventricle, includes anemia, 
hypertension and hypoalbuminemia. 
4. DILATED LEFT ATRIUM: 
         Dilated left atrium was present in 4 cases, out of which 3 had dilated left 
ventricle and systolic dysfunction. 
5. SYSTOLIC DYSFUNCTION: 
         Systolic dysfunction defined as Ejection fraction less than 55% or Fractional 
shortening less than 25% was found in 11(20.4%) patients. The incidence of 
systolic dysfunction in the study by Parfrey PS et al was 16%5. Mild systolic 
dysfunction was found in 5 patients. Moderate and severe systolic dysfunction 
accounted for each 3 patients respectively. 2 cases of Moderate dysfunction and 2 
cases of severe dysfunction were found in the dilated left ventricular group. This 
shows that dilated left ventricle is an independent risk for systolic dysfunction. 2 
patients had global hypokinesia of left ventricle with systolic and diastolic 
dysfunction. One of these patients had dilated left ventricle and left atrium and 
had the criteria fulfilled for Dilated Cardiomyopathy. 
 6. DIASTOLIC DYSFUNCTION: 
           Diastolic dysfunction was found in 15(27.8%) patients. Grade I           
diastolic dysfunction was found in 11 patients and grade II diastolic dysfunction 
was found in 4 patients. Of these 15 patients with diastolic dysfunction 8 patients 
had concentric left ventricular hypertrophy and 6 patients had dilated left 
ventricle. 
7. OTHER ABNORMALITIES: 
           Aortic valve calcification was found in 4(7.5%) cases. Aortic valve 
calcification can occur in End-stage Renal Disease due to secondary 
hyperparathyroidism and increased calcium phosphorus product. Age is also an 
important risk factor for Aortic valve calcification. The low incidence of             
Aortic valve calcification in the study could be attributed to exclusion of persons 
above 50 years of age from the study. Raine.A.E.G, has reported an incidence of 
28 to 55% of Aortic valve calcification in End-stage Renal Disease, with 3 to 13% 
having aortic stenosis52. 
         Moderate mitral regurgitation was found in 1 patient and mild mitral 
regurgitation was found in 7 patients. Rest of the valvular abnormalities included 
trivial mitral regurgitation, trivial tricuspid regurgitation and trivial aortic 
regurgitation. 1 patient had mitral valve prolapse which is an incidental finding. 
          Results of this study done in Stanley Medical College Hospital (SMCH), 
Chennai and the study done by Parfrey et al., in Division of Nephrology, 
Salvation Army Grace General Hospital, Canada can be summarized as follows: 
 
    Parameters       Present Study       Parfrey et al.,5  
 Concentric LVH           44.4%             41% 
 Dilated LV          25.9%             28% 
Systolic dysfunction          20.4%             16% 
Normal          14.8%            16% 
 
 
 
 
 
 
 
 SUMMARY 
 
 
• The study included a total of 54 patients with chronic kidney disease. There 
were 40 males and 14 females. Mean age was 30 years 
• Pedal edema, dyspnoea and chest pain were the common symptoms. 75% 
had symptoms more than 6 months. 
• Severe anemia occurred in 40%.  
• About 94.5% had serum Creatinine more than 5 mg/dl. 
• About 68.5% had stage 5 chronic kidney disease (Creatinine clearance < 15 
ml/min). 
• Normal chest X-Ray finding was present in 72.3%. 
• ECG revealed LVH with pressure overload pattern in 18.5%. Low voltage 
complexes was seen in 3.7%.   
• Echocardiography - pericardial effusion (46.3%) and concentric LVH 
(44.4%) were the common abnormalities. Dilated LV occurred in 25.9%, 
diastolic dysfunction in 27.8% and systolic dysfunction in 20.4%.  
 
 
 
                                            CONCLUSION 
 
1. Echocardiography is easily performed, non-invasive, safe, reproducible and 
accurate in assessment of cardiac function in chronic kidney disease. 
2. Pericardial effusion followed by concentric left ventricular hypertrophy were 
the commonest abnormalities in chronic kidney disease. 
3. In Echocardiography, pericardial effusion occurred in 46.3%, concentric LVH 
in 44.4%, dilated LV in 25.9%, diastolic dysfunction in 27.8% and systolic 
dysfunction in 20.4%. 
4. Echocardiography is more sensitive in diagnosing pericardial effusion and left 
ventricular hypertrophy than by X-Ray and ECG. 
5. Echocardiographically detectable mild pericardial effusion and concentric left 
ventricular hypertrophy were present in asymptomatic patients. Hence this 
necessitates screening of patients without cardiac symptoms for cardiac 
abnormalities immediately after the diagnosis of chronic kidney disease has been 
made. 
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                                                PROFORMA  
    
   
NAME:                                                              RESIDENCE: 
AGE:                                                              
SEX:   
SOCIO-ECONOMIC STATUS:                        IP NO: 
PRESENTING SYMPTOMS:                                         
                  Duration of symptoms: 
                   Dyspnoea                                          Chest pain  
                   Pedal edema                                      Giddiness    
                   Palpitation                                         Syncope 
                   Other symptoms 
 
PAST HISTORY: 
                  Hypertension     Y/N                         Duration of hypertension: 
                 Valvular heart disease    Y/N 
                 Coronary artery disease  Y/N  
                 NSAID use     Y/N  
                 Other drug intake: 
                 Habit of smoking    Y/N 
                If known CKD, duration of CKD: 
 
 2
EXAMINATION: 
                 Pallor                                                        JVP 
                 Pedal edema                                                
                 CVS:                                                          RS: 
                 Abdomen:                                                  CNS: 
                                                                                   Fundoscopy: 
                PR:                                                             RR: 
                BP:           1.                                               TEMP:                                          
                                 2. 
                                 3.                                                BODY WEIGHT: 
               Mean BP: 
 
INVESTIGATIONS: 
 
1) Complete hemogram: 
 
2) Urea:  
 
3) Sr. Creatinine: 
 
4) Creatinine clearance(Cockcroft-Gault): 
 
5) Blood sugar: 
 
6) Urine:  
 
               Albumin                                          Casts                       
               Sugar                                               Culture 
               Deposits                                           24-HR protein 
 
7) Sr. proteins: 
8) Sr. cholesterol:  
 3
9) Sr. uric acid:                                           10) Liver function tests: 
11) Sr. calcium: 
12) Sr. Phosphorus:                                      13) Sr. Electrolytes: 
14) USG abdomen:                                           
15) Renal biopsy: 
 
 
16) Chest X-Ray: 
 
 
17) ECG: 
 
 
18) ECHOCARDIOGRAPHY: 
   
        MEASUREMENTS: 
          
                IVS-S:                                           EDV: 
                               
                IVS-D:                                          ESV: 
 
                LVID-S:                                        SV: 
 
                LVID-D:                                       EF: 
 
               LVPW-S:                                       FS: 
 
               RWT:   
 
               Aorta:                                             Left atrium:  
 
        CHAMBERS: 
 
               LA:                                                  RA:      
        
               LV:                                                 RV:             
                                                                             
               SEPTAE:                                        CLOT: 
                 
 4
          LV WALL MOTION: 
          SYSTOLIC FUNCTION: 
          DIASTOLIC FUNCTION:  
         PERICARDIUM: 
     
         VALVES: 
 
         FINAL IMPRESSION OF ECHOCARDIOGRAPHY: 
 
 
                              
 
 
 
 
 
 
 
S,No 
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Age 
 
 
 
 
 
Sex 
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V
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CVS 
 
 
 
 
 
 
RS 
     
 
 
 
 
 
PR   
 
 
 
 
 
 
BP  
 
 
 
 
 
 
CAUSE 
 
 
 
 
 
 
Hb    
 
 
 
 
 
 
Urea   
 
 
 
 
 
 
Cr. 
 
 
 
 
 
 
Cr.cl 
 
 
 
 
 
 
USG abd 
 
 
 
 
 
 
C.X-ray 
 
  
  ECG 
1 Manivannan 22 M 6 mon PE + + N N N 84 150/110 CGN 8.6 198 16.4 7 ck N N 
2 Nagammal 35 F  2 yrs D,PE,P + + el AI-
down&out 
Bas.creps 91 170/100 CGN 7.7 68 3.5 17 ck Card, 
pul int 
ed 
N 
3 Kasirajan 26 M 11 mo D,PE, + + N N N 94 160/100 CGN 7.6 204 8.6 14 ck N LVH 
4 Dhanalakshmi 38 F 14 mo D,PE + + N N N 82 160/94 CGN 8.6 168 13.8 7 ck N N 
5 Habibullah 46 M  2yrs D,PE,CP + + el  N Bas.creps 106 140/90 CGN 7.8 158 7.1 14 ck N N 
6 Perumal 35 M  6 mo PE,D + + N N N 92 140/80 CGN 6.2 152 10.3 10 ck N N 
7 Shankar 16 M  4 mo D,PE,V + + N N N 90 140/80 CGN 7 158 7.5 15 ck N LVH 
8 Paul raj 40 M  3 Yrs PE,P + + el ESM-AA Bas.creps 86 170/90 ADPKD 6 166 8 15 ADPKD N N 
9 Bhuvaneshwari 17 F 4 mo PE + + el N Bas.creps 84 160/90 CGN 7.6 152 6.6 14 ck N N 
10 Munusamy 39 M 6 mo D,PE,V + + N N N 86 140/96 CGN 6.4 140 8 14 ck Card N 
11 Chengamuthu 27 M 7 mo PE + + N N N 82 130/90 CGN 5.6 188 16.5 8 ck N N 
12 Syed Mustafa 27 M 14 mo CP,D,PE + + N N Bas.creps 106 140/94 CGN 8.2 150 10.8 11 ck Card LVH 
13 Vijay Kumar 28 M 7 mo PE,D + + N ESM-AA N 86 150/90 CGN 6.4 148 8.3 14 ck N N 
14 Shafee 18 M 7 mo PE,V + + el PSM-MA Bas.creps 100 160/80 IgA Neph 8 187 12.7 9 ck,GR2 
PC 
Card 
,pul int 
ed 
N 
15 Shanthi 37 F 1 Yr PE,P,CP + + el N Bas.creps 90 170/100 CGN 5 152 8.8 12 ck Card LVH 
16 Abdul Salam 31 M 2 Yrs D,PE + + N N N 76 142/86 CGN 9.6 138 6 17 ck N N 
17 Kumeresan 26 M 16 mo PE + + N N N 78 160/100 CGN 6 162 7.1 18 ck N N 
18 Vallava Das 31 M 6 mo PE,D,V + + el N Bas.creps 112 160/90 CGN 7.7 188 9.4 11 ck N N 
19 Raj Mohan 32 M 6 mo PE,CP + + N N N 80 160/90 CGN 7.8 178 8.2 16 ck Card LVH 
20 Ramesh Kumar 19 M 5 mo D,PE + + N N N 82 130/90 CGN 7 180 9.2 12 ck N N 
21 Kalai Selvi 33 F 9 mo D,PE,V,CP + + el AI-
down&out 
Bas.creps 96 170/100 CGN 6.4 168 10.7 9 ck Card N 
22 Dhayalan 37 M 4 mo D,PE,P + + el PSM-MA Bas.creps 80 190/100 CGN 7.6 147 6.2 20 ck N N 
23 Sreenivasan 32 M 14 mo D,PE + + N ESM-AA N 102 150/96 Obs.Neph 5 148 6.5 19 ck,Ct N N 
24 Ramesh  27 M 4 mo D,CP + + N N N 96 130/90 CGN 8 128 5.2 22 ck N LVH 
25 Shiva kumar 26 M 1 Yr PE,P + + N N N 88 140/90 CGN 7.2 148 7.8 14 ck N N 
26 Malini Devi 16 F 4 mo PE,D + + N N N 86 140/86 CGN 5.9 120 12.6 8 ck N N 
27 Abdullah 36 M 13 mo  D,PE + + N N N 70 170/116 CGN 9.8 178 15.1 7 ck N LVH 
28 Narendran 24 M 6 mo PE,CP + + N N N 91 146/80 CGN 7.2 140 9.8 13 ck N N 
29 Sundaram 30 M 8 mo PE + + el N Bas.creps 86 140/100 CGN 7.2 176 10.7 12 ck Card N 
30 Karpagasumathy 19 F 5 mo PE + + N N N 84 140/90 CGN 8 130 11.3 8 ck N N 
31 Lakshmipathy 25 M 2Yrs PE,D + + N PR+ N 80 150/90 IgA Neph 6.6 150 8 16 ck,Gr 3 
PC 
N N 
32 Mahendran 20 M 7 mo PE,D + + el HS muf N 81 170/100 CGN 6 149 6.9 19 ck Card Low 
Vol 
33 Loganathan 45 M 5 mo PE − + N N N 86 130/90 Obs.Neph 11 104 4.9 24 B.HUN,ct N N 
 
 
 
PE  - pedal edema                                               Ct – cortical thinning 
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Cr. 
 
 
 
 
 
 
Cr.cl 
 
 
 
 
 
 
USG abd 
 
 
 
 
 
 
C.X-ray 
 
  
  ECG 
34 Syed Mansoor 35 M 1 Yr PE,D + + el N Bas.creps 76 174/110 CGN 8 170 11 11 Ck Card N 
35 Chella Muthu 36 M 2 Yrs PE,D + + N N N 84 170/100 CGN 6.4 188 13.5 9 Ck N N 
36 Venkatesh 25 M 4 mo D + + N N N 70 140/90 CGN 8 160 9 14 Ck N N 
37 Anbazhagan 41 M 6 mo D,PE,CP + + el N N 74 170/90 CGN 9.2 172 14.4 9 Ck Card N 
38 Vijaya 40 F 6 mo PE,D,P + + N N N 74 140/86 CGN 7.4 156 8.1 11 Ck N LVH 
39 Subramani 31 M 7 mo PE,D + + N ESM-AA N 84 160/110 CGN 6 102 4.8 27 Ck N N 
40 Ganga 28 F 8 mo PE,D + + el N N 102 160/90 CGN 6 168 9.3 11 ck N N 
41 Hassan 
Mohammed 
26 M 18 mo PE + + N N N 86 160/110 CGN 8.8 160 8.2 15 ck N N 
42 Ramalingam 48 M 1 Yr PE,D + + N N N 84 150/100 CGN 6 144 12.2 7 ck N N 
43 Amjath Basha 22 M 1 Yr PE,D + + el ESM-AA Bas.creps 98 150/90 CGN 6 132 12.8 9 ck Card,pul 
int ed 
N 
44 Arumugham 28 M 5 mo PE,D + + N N N 84 170/90 CGN 7.2 148 5.8 21 ck N N 
45 Selvaraj 36 M 6 mo D,PE,CP + + N N N 102 140/90 CGN 6.5 186 15 8 ck N LVH 
46 Mahizhan 31 M 3 mo V + − N N N 86 170/90 CGN 8.2 146 15.4 7 ck N N 
47 Sangeetha 18 F 10 mo D,PE + + N N N 76 150/100 CGN 6.6 120 8.6 10 ck Card N 
48 Ramachandran 40 M 4 mo D,PE + + N N N 86 140/90 CGN 6.8 180 12 10 ck N N 
49 Hemavathy 16 F 3 mo D,PE + + N N N 82 130/90 IgA Neph 9 128 5.8 15 ck N N 
50 Suresh 43 M 11 mo PE,P + + El N N 87 160/90 CGN 6.4 166 7.5 14 ck N N 
51 Usha 13 F 6 mo PE,D + + El HS muf Bas.creps 72 140/90 CGN 7.8 168 10.9 8 ck Card Low 
Vol 
52 Vijayalakshmi 36 F 9 mo PE,D + + El N Bas.creps 96 170/110 CGN 6.6 140 8.6 12 ck Card N 
53 Jeyapriya 16 F 3 mo V,D − − N N N 84 130/84 CGN 10.8 128 8 10 ck N N 
54 Gowri Shankar 34 M 1 Yr PE,D,CP + + El N Bas.creps 100 160/108 CGN 8.6 140 6.2 19 ck N LVH 
D – dyspnoea                                                       B.HUN – bilateral hydroureteronephrosis.  
CP – chest pain                                                    card – cardiomegaly 
P – palpitation                                                      pul int ed – pulmonary interstitial edema 
V – vomiting                                                        el – elevated 
 
CGN – chronic glomerulonephritis                     HS muf – heart sounds muffled 
Obs. Neph – obstructive nephropathy                 LVH – left ventricular hypertrophy  
IgA Neph – IgA nephropathy                              Low vol – low voltage complexes 
Gr 2 PC – grade 2 parenchymal changes 
Ck – contracted kidneys 
